+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Incidence and impact of adverse drug events contributing to hospital readmissions in kidney transplant recipients



Incidence and impact of adverse drug events contributing to hospital readmissions in kidney transplant recipients



Surgery 163(2): 430-435



The incidence and impact of adverse drug events (ADEs) leading to hospitalization and as a predominant risk factor for late graft loss has not been studied in transplantation. This was a longitudinal cohort study of adult kidney recipients transplanted between 2005 and 2010 and followed through 2013. There were 3 cohorts: no readmissions, readmissions not due to an adverse drug event, and adverse drug events contributing to readmissions. The rationale of the adverse drug events contribution to the readmission was categorized in terms of probability, preventability, and severity. A total of 837 patients with 963 hospital readmissions were included; 47.9% had at least one hospital readmission and 65.0% of readmissions were deemed as having an ADE contribute. The predominant causes of readmissions related to ADEs included non-opportunistic infections (39.6%), opportunistic infections (10.5%), rejection (18.1%), and acute kidney injury (11.8%). Over time, readmissions due to under-immunosuppression (rejection) significantly decreased (-1.6% per year), while those due to over-immunosuppression (infection, cancer, or cytopenias) significantly increased (2.1% increase per year [difference 3.7%, P = .026]). Delayed graft function, rejection, creatinine, graft loss, and death were all significantly greater in those with an ADE that contributed to a readmission compared the other two cohorts (P < .05). These results demonstrate that ADEs may be associated with a significant increase in the risk of hospital readmission after kidney transplant and subsequent graft loss.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 065230428

Download citation: RISBibTeXText

PMID: 29174434

DOI: 10.1016/j.surg.2017.09.027


Related references

Medication errors and adverse drug events in kidney transplant recipients: incidence, risk factors, and clinical outcomes. PharmacoTherapy 32(12): 1053-1060, 2012

Hospital readmissions in diabetic kidney transplant recipients with peripheral vascular disease. Clinical Transplantation 32(6): E13271, 2018

The impact of major intraoperative adverse events on hospital readmissions. American Journal of Surgery 213(1): 10-17, 2017

Role of in-hospital care quality in reducing anxiety and readmissions of kidney transplant recipients. Journal of Surgical Research 205(1): 252-259.E1, 2016

Immune depression as a contributing factor to a high incidence of skin cancer in kidney transplant recipients. Transplantation Proceedings 16(4): 1002-1004, 1984

Kidney transplant recipients and the incidence of adverse reactions to cyclosporin. Saudi Medical Journal 25(10): 1499-1500, 2004

Predicting potential postdischarge adverse drug events and 30-day unplanned hospital readmissions from medication regimen complexity. Journal of Patient Safety 10(4): 186-191, 2014

Usefulness of mycophenolic acid monitoring with PETINIA for prediction of adverse events in kidney transplant recipients. Scandinavian Journal of Clinical and Laboratory Investigation 76(4): 296-303, 2016

A clinical tool to risk stratify potential kidney transplant recipients and predict severe adverse events. Clinical Transplantation 30(11): 1494-1500, 2016

Impact of sample size on variation of adverse events and preventable adverse events: systematic review on epidemiology and contributing factors. Quality and Safety in Health Care 19(6): E24, 2010

Impact of Epstein-Barr virus donor and recipient serostatus on the incidence of post-transplant lymphoproliferative disorder in kidney transplant recipients. Nephrology Dialysis Transplantation 27(7): 2971-2979, 2012

Time-varying maximal proteinuria correlates with adverse cardiovascular events and graft failure in kidney transplant recipients. Nephrology 20(12): 945-951, 2015

Hospital Admission following Acute Kidney Injury in Kidney Transplant Recipients Is Associated with a Negative Impact on Graft Function after 1-Year. Plos one 10(9): E0138944, 2015

Effect of baseline renal and hepatic function on the incidence of adverse drug events: the Japan Adverse Drug Events study. Drug Metabolism and Personalized Therapy 33(4): 165-173, 2018

Impact of a Clinical Solid Organ Transplant Pharmacist on Tacrolimus Nephrotoxicity, Therapeutic Drug Monitoring, and Institutional Revenue Generation in Adult Kidney Transplant Recipients. Progress in Transplantation 26(4): 314-321, 2016